Hybrid Event: Healthcare Innovation & Strategy Series - Healthcare is Getting Personal!

No items found.
​
21 September 2021
Tags
No items found.

We would like to invite you to join us for our largest ever life science and medtech hybrid event on 14 October where we will be exploring upcoming trends in IP and healthcare.

This event will explore the continuing trend of providing personalised healthcare and medicines to individual patients, as well as looking ahead at the opportunities that digital health will bring. We will also have expert guidance on the importance of brand protection in this sector.

Speakers will include experts from EIP's HealthTech, Elements and Life Practice Groups as well as Professor Ruth Goodridge, Professor of Additive Manufacturing (3D Printing) at the University of Nottingham, Joanna Holbrook, Senior Vice President of Research at Cambridge Epigenetix, and Julius Stobbs, Founding Principal at Stobbs.

The full schedule is available to view here.

All delegates will leave with key takeaways on the future of IP and healthcare including the risk and opportunities this emerging area offers.

Ready to learn more about the challenges faced by innovators in this exciting sector? Register here.



Related articles

EIP strengthens Swedish presence with dedicated Malmö office
10 November 2026
EIP has strengthened its presence in Sweden with a dedicated Malmö office, reflecting the continued growth of our team in southern Sweden. The Malmö team supports innovative businesses with intellectual property expertise, helping them protect their ideas and maximise their commercial value.
EIP named in The Times Best Law Firms for a second year running
05 November 2026
EIP have been named in The Times Best Law Firms 2027 and commended for intellectual property, for the second consecutive year.
EIP ranked Band 1 in Chambers UK 2027, with three lawyers also recognised
14 October 2026
Chambers recognised EIP for its patent litigation work and its strength in disputes concerning FRAND licensing and standard essential patents.